At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.


French German Italian Portuguese Russian

HERO-HCQ Trial: Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial

Clinical Trial Title: 
Healthcare worker exposure response and outcomes of hydroxychloroquine trial (HERO-HCQ Trial): A trial to evaluate the efficacy of hydroxychloroquine to prevent COVID-19 in healthcare workers.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Yoona Rhee, MD
Clinical Trial Protocol Description: 

Eligible participants will be randomly assigned (1:1) to either treatment group (HCQ) or placebo in a double-blind fashion. Course of treatment is 30 days and is as follows: HCQ/placebo tablet 600mg bid (twice) loading dose on day 1, followed by 400mg on days 2-30. There will be two on-site visits and four remote visits over an approximately 60 day period during which participants will complete various Quality of Life (QoL) questionnaires, provide serum samples, and undergo nasopharyngeal swabs for COVID-19 testing.

Note: This is an outpatient clinical trial.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Complete Informed Consent.
  • Are at least 18 years of age and able to speak and read English or Spanish.
  • Are currently working with a trial participating site where individuals receive healthcare ("healthcare worker") or are associated with the site through emergency services or related healthcare services.
  • Are at risk for COVID-19 infection through one or more of the following work exposures:
    • In the intensive care unit
    • In the emergency department
    • In emergency services
    • In a COVID-19 hospital unit/ward
    • In respiratory services
    • In COVID-19 testing location
    • In inpatient hospital unit/area with potential COVID-19 cases
    • In long-term care, assisted living or skilled nursing facilities

This is a partial list of elgibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Clinical Trial Area: 
Contact Email: 
Contact Phone: 
(312) 942-5865
Contact Name: 
Yoona Rhee, MD